References
- Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to2008. J Clin Oncol2011;29:2514–2520.
- Gruber FX, Ernst T, Porkka K, et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 2012;26:172–177.
- O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
- Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009; 114:5271–5278.
- Faber E, Kuba A, Zapletalova J, et al. Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia. J Interferon Cytokine Res 2012;32:230–234.
- Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011;118:3228–3235.
- Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011;6:e23022.
- de Castro FA, Palma PV, Morais FR, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 2003;44:2061–2067.
- Preuner S, Denk D, Frommlet F, et al. Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia 2008;22:1956–1961.
- Jalkanen SE, Vakkila J, Kreutzman A, et al. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. Exp Hematol 2011;39:102–113.e1.
- Dalbeth N, Gundle R, Davies RJ, et al. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004;173:6418–6426.
- Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633–640.
- Solana R, Tarazona R, Gayoso I, et al. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012;24:331–341.
- Fathy A, Eldin MM, Metwally L, et al. Interferon therapy shifts natural killer subsets among Egyptian patients with chronic hepatitis C. Braz J Infect Dis 2010;14:398–405.
- Jacobs R, Hintzen G, Kemper A, et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001;31:3121–3127.
- de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007;110:2779–80.
- Itonaga H, Tsushima H, Hata T, et al. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol 2012;95:209–213.